- Source: Cantuzumab
Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen.
It is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates :
Cantuzumab mertansine
Cantuzumab ravtansine
huC242 targets CanAg
"HuC242 binds to the extracellular domain of the tumor-associated carbohydrate antigen known as CanAg (a novel glycoform of MUC1). CanAg is strongly expressed in most pancreatic, biliary, and colorectal cancers. It is also expressed in a substantial proportion of gastric cancers (55%), uterine cancers (45%), non-small cell lung cancers (40%), and bladder cancers (40%)."
References
Kata Kunci Pencarian:
- Cantuzumab
- Cantuzumab ravtansine
- Cantuzumab mertansine
- List of drugs: C–Ca
- Mertansine
- Ravtansine
- List of therapeutic monoclonal antibodies
- Indium (111In) altumomab pentetate
- Naptumomab estafenatox
- Index of immunology articles
